DAWN Day One Biopharmaceuticals, Inc.
Healthcare$21.53+0.00%ClosedMarket Cap: $2.22B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
5.05
P/S
14.06
EV/EBITDA
-16.38
DCF Value
$55.67
FCF Yield
-4.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.1%
Operating Margin
-80.8%
Net Margin
-67.8%
ROE
-23.4%
ROA
-21.1%
ROIC
-28.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $53.7M | 88.7% | $-27.5M | $-21.3M | $— | — |
| FY null | $158.2M | 89.1% | $-127.8M | $-107.3M | $— | — |
| Q3 null | $39.8M | 88.7% | $-24.3M | $-19.7M | $— | — |
| Q2 null | $33.9M | 88.9% | $-35.0M | $-30.3M | $— | — |
| Q1 null | $30.8M | 90.6% | $-41.1M | $-36.0M | $— | — |
| Q4 null | $29.2M | 89.8% | $-65.3M | $-65.7M | $— | — |
| FY null | $131.2M | 96.0% | $-217.3M | $-95.5M | $— | — |
| Q3 null | $93.8M | 98.3% | $29.6M | $37.0M | $— | — |
| Q2 null | $8.2M | 91.4% | $-114.8M | $-4.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-66.8M | $-62.4M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-59.5M | $-54.5M | $-0.62 | — |
| FY null | $0.00 | NaN% | $-206.1M | $-188.9M | $— | — |